pegulicianine acetate - Profile
✉ Email this page to a colleague
What are the generic drug sources for pegulicianine acetate and what is the scope of patent protection?
Pegulicianine acetate
is the generic ingredient in one branded drug marketed by Lumicell and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Pegulicianine acetate has twenty-three patent family members in seven countries.
Summary for pegulicianine acetate
| International Patents: | 23 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for pegulicianine acetate
Generic Entry Date for pegulicianine acetate*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for pegulicianine acetate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | 10,285,759 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | 9,763,577 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | 9,532,835 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | 9,155,471 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | 9,032,965 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | 11,592,396 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for pegulicianine acetate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2646057 | PROCÉDÉS ET SYSTÈMES DESTINÉS À IDENTIFIER SPATIALEMENT DES CELLULES ANORMALES (METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS) | ⤷ Start Trial |
| Australia | 2016277654 | METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS | ⤷ Start Trial |
| Australia | 2014236561 | Medical imaging device and methods of use | ⤷ Start Trial |
| Japan | 7273873 | ⤷ Start Trial | |
| Japan | 2016520339 | 医用撮像装置と使用方法 | ⤷ Start Trial |
| Australia | 2011336660 | Methods and systems for spatially identifying abnormal cells | ⤷ Start Trial |
| European Patent Office | 3695853 | SONDES D'IMAGERIE MOLÉCULAIRE ET LEURS COMPOSITIONS (MOLECULAR IMAGING PROBES AND THEIR COMPOSITIONS) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
